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Abstract
A higher levodopa dose is a strong risk factor for levodopa-induced dyskinesia (LID) in
patients with Parkinson’s disease (PD). However, levodopa dose can change during long-
term medication. We explored the relationship between levodopa dose and time to onset of
LID using longitudinal multicenter data. Medical records of 150 patients who were diagnosed
with de novo PD and treated with levodopa until onset of LID were collected. Levodopa dose
were assessed as the dose at 6 months from levodopa initiation and rate of dose increase
between 6 months and onset of LID. The groups with earlier LID onset had higher levodopa
and levodopa-equivalent dose at the first 6 months of treatment and rapid increase in both
levodopa and levodopa-equivalent dose. Multivariable linear regression models revealed
that female sex, severe motor symptom at levodopa initiation, and higher rate of increase in
both levodopa and levodopa-equivalent dose were significantly associated with early onset
of LID. The present results demonstrated that rapid increase in levodopa dose or levodopa-
equivalent dose is associated with early onset of LID.
Introduction
Levodopa improves motor symptoms in patients with Parkinson’s disease (PD). However,
many patients treated with levodopa chronically encounter levodopa-induced dyskinesia
(LID). LID develops in approximately 60% of patients within at 5 years of levodopa therapy
[1–3], and it eventually affects most of patients treated with levodopa [1, 4, 5].
Previous studies have determined risk factors for LID to be younger age at PD onset [1, 4, 6,
7], female sex [7], lower body weight [7], higher levodopa dose [1, 4, 6, 7], and more severe
motor symptoms at baseline [7–9], lower dopamine transporter availability at baseline [6, 9],
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and higher dopamine turnover rate in the posterior putamen at baseline [10]. Among these
risk factors, high levodopa dose is one of the most commonly reported; however, there was no
established method for assessing levodopa dose which is usually increased during long-term
therapy. In previous studies, levodopa dose has been defined as the initial dose [1, 4], cumula-
tive dose [8], or dose at LID onset/last dose in LID-free patients [6, 7]. However, the levodopa
dose usually increases with disease progression in general practice and clinical trials [3, 11],
and the rate of dose increase varies among patients.
Results from clinical trials consistently showed that parkinsonian motor symptoms
improved within 6 to 9 months from the initiation of medication and then progressed again
with a constant rate [2, 3, 12, 13]. Similar to clinical trials, observational studies have also
shown that the initial drug dose is titrated within 6 to 12 months from the initiation of medica-
tion [1, 4, 14], and the rate of subsequent dose increases is similar for many years [14]. There-
fore, assessing levodopa dose using initial titration dose and rate of dose increase can help
analyzing the longitudinal effect of levodopa dose on development of LID.
In this study, we collected longitudinal data on levodopa dose from patients with PD who
experienced LID during medical therapy, and we explored the relationship between levodopa
dose and time to development of LID.
Materials and methods
Subjects
We reviewed medical records from 4 referral hospitals in South Korea (Wonju Severance
Christian Hospital, Bundang Jesaeng General Hospital, Severance Hospital, Dongtan Sacred
Heart Hospital, and Severance Hospital) between March 2007 and October 2018 and selected
data of PD patients who experienced LID. PD was diagnosed according to the clinical criteria
of UK PD brain bank [15], and patients who showed atypical features listed in step 2 of the cri-
teria during treatment period were excluded from the study. Patients who had been treated
with dopaminergic drugs or dopamine receptor blocking agents before visiting our hospitals
were also excluded. Among them, we selected patients who initiated medical treatment with
levodopa. Patients who took dopamine agonist or monoamine oxidase B (MAO-B) inhibitor
prior to levodopa initiation, a dopamine-receptor blocking agent during treatment period, or
amantadine before development of LID were also excluded. Patients with impulse control dis-
orders, psychosis, or dementia were not included because these conditions may affect drug
dose.
LID was assessed based on medical record. For regular management for PD, patients usu-
ally have been visiting outpatient clinic of 5 experts in movement disorders (J.Y.H., M.K.S., S.
Y.K., Y.H.S., and P.H.L.) every 2–3 months. When patient reported symptom suggesting LID
or dyskinetic movement was observed in the clinic, clinicians recorded the information for
LID. The onset of LID was defined as 1) the first day that LID was observed by clinician
when patient did not perceive their dyskinesia, 2) the day indicated by patient when LID was
observed by clinician and the patient remembered the day that LID had begun. Patients who
skipped visit more than 6 months were excluded from the study. Because short latency to
onset of LID may make rate of dose increase overestimated, patients who LID developed
within 2 years from levodopa initiation were excluded.
Subjects were grouped according to time to development of LID from initiation of levo-
dopa: E (Early, 2 years < time to LID onset� 4 years), M (Middle, 4 years< time to LID
onset� 6 years), L (Late, 6 years < time to LID onset).
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Ethics statement
The study protocol was approved by the Institutional Review Board (IRB) of the Wonju Sever-
ance Christian Hospital (approval number: 2018-10-0007), and the study was conducted
according to the Declaration of Helsinki. The requirement for written informed consent was
exempted by the IRB and local regulation due to the retrospective design.
Drug dose
Patients took equal dose of levodopa three times a day, and the treatment was usually initiated
with 50mg of levodopa three times a day. When dose increase was needed, the single dose was
usually increased by 50mg (150mg a day). Data for the dose of antiparkinsonian drugs at 6
months, 1 year, and every year after that from initiation of levodopa were collected from pre-
scription records. The levodopa-equivalent dose (LED) was calculated according to a pub-
lished formulation [16].
To reflect change of drug dose over disease progression, the drug dose was assessed as initial
titration dose and rate of dose increase. Initial titration dose was defined as the daily dose of
levodopa at 6 months from the initiation of medication [14], and the rate of dose increase was
calculated as following: {(drug dose at onset of LID)–(drug dose at 6 months [initial titration
dose])} / {(years at onset of LID)–(0.5 year)}. Initial titration dose and rate of dose increase for
LED were calculated with same method.
Statistical analyses
Analysis of variance (ANOVA) and chi-square test were used to compare groups, and post hoc
analyses were conducted with Bonferroni’s method. Factors associated with time to LID onset
were explored using Pearson’s correlation and multivariable linear regression models with
stepwise selection method. Because data for UPDRS motor score of 61 patients were missed,
linear regression analyses were conducted with data from 89 patients. Statistical analyses were
performed with SPSS Statistics 23 (IBM SPSS, Armonk, NY, USA), and p<0.05 was considered
significant. Graphic illustrations were obtained using GraphPad Prism version 7.02 for Win-
dows (GraphPad Software, La Jolla, CA, USA).
Results
Demographic and clinical characteristics
According to the inclusion and exclusion criteria of this study, a total of 150 patients were col-
lected for this study (58 for E, 51 for M, and 41 for L group). Demographic and clinical charac-
teristics of study subjects are presented in Table 1. Sex, age at PD onset, age at initiation of
levodopa therapy, and time between PD onset and initiation of levodopa therapy did not differ
significantly among groups. UPDRS motor score at levodopa initiation were higher in E (29.2
vs. 22.1, post hoc p = 0.029) than L group, however modified Hoehn and Yahr stage was not
different among groups.
Drug dose
The mean levodopa dose and LED over time according to the groups are shown in Fig 1, and
data for initial titration dose and rate of dose increase are presented in Table 1. Initial titration
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dose of levodopa and LED were similar among groups. The rate of levodopa increase was
higher in E group than L group (69.9 vs. 41.5 mg/day/year, post hoc p = 0.034), and rate of LED
increase was higher in E group than both M (113.8 vs. 75.8 mg/day/year, post hoc p = 0.019)
and L groups (113.8 vs. 63.3 mg/day/year, post hoc p = 0.002). Both levodopa dose and LED at
onset of LID were not significantly different among groups. The frequency of use of other anti-
parkinsonian drugs other than levodopa at onset of LID did not differ among groups.
Risk factor for early LID
Pearson’s correlation analysis (Fig 2) revealed that time to onset of LID was correlated with
initial titration dose of levodopa (r = -0.17, p = 0.043), rate of dose increase for levodopa (r =
-0.21, p = 0.009) and LED (r = -0.29, p<0.001), UPDRS motor score (r = -0.31, p = 0.003), and
modified Hoehn and Yahr stage (r = -0.22, p = 0.033). Initial titration dose of LED tended to
correlate with time to onset of LID (r = -0.15, p = 0.066). However, time to onset of LID was
not associated with age at onset of PD, age at levodopa initiation, time between PD onset and
initiation of levodopa therapy, sex difference, and use of dopamine agonist, MAO-B inhibitor,
entacapone, or anticholinergics.
Multivariable linear regression models for levodopa dose (F = 7.204, p<0.001, R2 = 0.203)
exhibits that female sex (β = -0.846, p = 0.028), higher rate of levodopa increase (β = -0.010,
p = 0.004), and higher UPDRS motor score at baseline (β = -0.054, p = 0.003) were associated
with early onset of LID (Table 2). Linear regression model for LED (F = 9.716, p<0.001,
R2 = 0.255) also found that female sex (β = -0.831, p = 0.024), higher rate of LED increase
Table 1. Demographic and clinical characteristics of subjects and drug dose.
Total (n = 150) E (n = 58) M (n = 51) L (n = 41) p-value Intergroup comparison
Female, n (%) 94 (62.7) 40 (69.0) 29 (56.9) 25 (61.0) 0.413
Age at PD onset, year 63.9 ± 8.7 62.9 ± 8.9 64.0 ± 8.4 65.1 ± 8.6 0.469
Age at levodopa initiation, year 65.3 ± 8.4 64.4 ± 8.6 65.4 ± 8.2 66.5 ± 8.6 0.470
PD onset to levodopa initiation, year 1.4 ± 1.2 1.5 ± 1.2 1.4 ± 1.1 1.4 ± 1.4 0.842
UPDRS motor score a 27.2 ± 10.0 29.2 ± 8.5 27.7 ± 11.9 22.1 ± 8.5 0.033 E>L
Modified Hoehn & Yahr stage b 2.2 ± 0.5 2.2 ± 0.5 2.1 ± 0.5 2.0 ± 0.3 0.283
Levodopa dose
Initial titration dose (at 6 months) 383.3 ± 140.9 406.9 ± 161.1 382.6 ± 133.2 350.6 ± 113.5 0.147
Rate of increase, mg/day/year 54.1 ± 55.5 69.9 ± 70.6 46.1 ± 45.7 41.5 ± 33.9 0.019 E>L
Dose at LID onset, mg/day 596.7 ± 220.6 578.0 ± 226.0 583.8 ± 190.1 639.0 ± 246.5 0.353
Levodopa-equivalent dose
Initial titration dose (at 6 months) 505.5 ± 154.7 518.6 ± 168.9 517.8 ± 148.4 460.9 ± 135.9 0.129
Rate of increase, mg/day/year 87.1 ± 74.2 113.8 ± 91.6 75.8 ± 63.5 63.3 ± 41.2 0.001 E>M, E>L
Dose at LID onset, mg/day 841.3 ± 258.4 797.6 ± 262.1 848.3 ± 253.4 894.4 ± 254.7 0.181
Drug use at LID onset, n (%)
Dopamine agonists 119 (79.3) 41 (70.7) 45 (88.2) 33 (80.5) 0.076
MAO-B inhibitors 44 (29.3) 14 (24.1) 17 (33.3) 13 (31.7) 0.532
Entacapone 60 (40.0) 20 (34.5) 19 (37.3) 21 (51.2) 0.218
Anticholinergics 19 (12.7) 8 (13.8) 7 (13.7) 4 (9.8) 0.806
PD, Parkinson’s disease; UPDRS, Unified PD rating scale; LID, levodopa-induced dyskinesia; MAO-B, monoamine oxidase B.
a Data of 89 patients (41 for E, 29 for M, and 19 for L group) existed.
b Data of 92 patients (42 for E, 29 for M, and 21 for L group) existed.
https://doi.org/10.1371/journal.pone.0237472.t001
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(β = -0.009, p<0.001), higher UPDRS motor score at baseline (β = -0.053, p = 0.003) were asso-
ciated with early onset of LID.
Discussion
The present study was conducted with a relatively large number of patients with LID and
explored the effect of longitudinal changes in levodopa dose or LED on time to onset of LID.
The results demonstrated that higher rate of dose increase of dopaminergic drugs were signifi-
cantly associated with the early onset of LID.
Patients who developed LID early had more severe motor symptoms at initiation of levo-
dopa therapy than did patients with late onset of LID, as in previous studies [7–9]. Functional
neuroimaging studies also demonstrated that lower dopaminergic activity in de novo patients
predicts early LID onset [6, 9, 10, 17]. The association between early onset of LID and higher
initial levodopa dose was also observed in previous studies. The mean levodopa dose over the
first 6 months [1] and maintenance dose of levodopa within the first year [4] were predictors
of early onset of LID. Given that motor symptoms and initial dose of dopaminergic drug may
reflect the severity of motor symptoms at diagnosis, these findings agree with previous reports
suggesting that more severe dopaminergic denervation when beginning treatment is a risk fac-
tor for LID [1, 4]. In the present study, initial titration dose of levodopa or LED showed signifi-
cant negative correlation with time to onset of LID, however the final regression models
Fig 1. Levodopa and levodopa equivalent dose. Levodopa (a) and levodopa equivalent dose (b) of each subjects. Left and right ends of each light line
indicate initial titration dose and dose at onset of LID of each subject, respectively. The mean doses of subject groups are expressed as heavy lines.
https://doi.org/10.1371/journal.pone.0237472.g001
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included UPDRS motor score at baseline instead of initial titration dose. This implies that ini-
tial titration dose does not act as an independent risk factor for early onset of LID, but just
reflects the severity of motor symptom at initiation of levodopa therapy.
The present data demonstrated that the rate of increase in levodopa dose or LED during
treatment is a significant predictor of early onset of LID. Generally, physicians increase the drug
dose when the motor symptoms get worse, which means that the rate of dose increase may
reflect disease progression. A recent study using serial SPECT imaging data also demonstrated
Fig 2. Time to onset of levodopa-induced dyskinesia and drug dose. Correlation between time to onset of levodopa-induced dyskinesia (LID)
and initial titrating levodopa dose (a), time to LID and initial titrating levodopa-equivalent dose (b), time to LID and rate of increase in levodopa
dose (c), and time to LID and rate of increase in levodopa-equivalent dose (d).
https://doi.org/10.1371/journal.pone.0237472.g002
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more rapid decrease on putaminal dopamine transporter activity in patients with LID com-
pared with patients without LID [9]. Therefore, the present results supports that rapid degenera-
tion of the dopaminergic system is associated with early onset LID.
The levodopa dose and LED at onset of LID of individual patient varied, however the mean
dose at onset of LID among patients groups were not different. This suggests that reaching par-
ticular level of levodopa dose may be associated with onset of LID. Both higher initial titration
dose and rapid dose increase shorten the time to reach a patient-specific drug threshold where
the LID develops. However the present results cannot determine which is related with the
early onset of LID, the severity of dopaminergic deficit or higher levodopa dose. No clinical tri-
als with a fixed dose of levodopa for several years have been conducted, therefore it is unclear
that levodopa dose is the independent risk factor for early onset of LID regardless of severity of
dopaminergic denervation. On the other hand, several previous studies have shown that a sin-
gle administration of overdosed levodopa also induces peak-dose dyskinesia in patients with
advanced PD who have never experienced LID before [18, 19], which suggests that long-term
exposure to levodopa is not a prerequisite for development of LID in some patients. Therefore,
further studies with more evidence are required to clarify whether dopaminergic drug truly
induces LID or simply acts as a trigger for onset.
Several limitations of this study need to be addressed. Drawing concrete conclusions from
this study is difficult because of its retrospective design without randomized allocation of drug
use. Many factors can influence physician choice of drug dose, such as patient age, drug com-
pliance, cognitive status, psychiatric symptoms, and adverse events. Finally, patients who expe-
rienced LID within 2 years from levodopa initiation were excluded due to the study design,
therefore it is unclear that the study findings are valid in patients with very early LID.
In conclusion, present study demonstrated that rapid dose increase of dopaminergic drug
is associated with early onset of LID. However, further studies are required to reveal which is
the determinant of onset of LID, severity of the disease or dose of dopaminergic drug.
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